Microneedle patch testing to predict allergy treatment response
Part of Ear, nose & throat, Immune system & allergy, Lungs & breathing clinical trials.
This study uses a small microneedle patch to collect skin-related samples to help predict how well allergy immunotherapy may work. It includes people with house dust mite allergy and also a healthy control group, so researchers can compare biomarker results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 19 to 60 years old
- Have allergic rhinitis caused by house dust mites, confirmed by allergy blood/skin testing (MAST Class 3+ or ImmunoCAP 3.5 kUA/L+)
- Have moderate to severe persistent nasal allergy symptoms (per ARIA severity criteria)
- For the house dust mite group, agree to use the microneedle patch and sign written informed consent
- For the healthy control group, be free of allergic or skin diseases and agree to provide human samples
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether dust-mite allergy treatment (likely allergy shots) can reduce allergy symptoms and improve safety. It focuses on people whose nose/eye allergy is triggered by house dust mites and who may also have controlled asthma.
This phase 3 trial tests a specific allergy treatment (an “immunotherapy” shot) for people whose symptoms are triggered by grass and cypress tree pollen. It aims to see if the treatment is safer and more effective at reducing allergy symptoms over time, especially for nose/eye symptoms and some people with asthma.
This trial tests a treatment called washed microbiota transplantation, which transfers gut bacteria from healthy donors to people with allergic rhinitis. The goal is to see if changing the gut bacteria can reduce allergy symptoms like sneezing, itching, and a runny or blocked nose.
This trial tests an under-the-tongue tablet for people with dust mite allergies causing moderate to severe nasal symptoms or mild-to-moderate asthma. The goal is to see if it improves symptoms and can replace or reduce the need for allergy medicines.
This trial tests if allergy shots (allergen-specific immunotherapy) can reduce symptoms of moderate to severe dust mite allergy. You will be in a room that exposes you to dust mites to see how well the treatment works, compared to a placebo.
This trial tests a new allergy shot that may reduce symptoms of dust mite allergies, like sneezing, runny nose, and itchy eyes. It might also help with mild asthma caused by dust mites.
Hear when a new Rhinitis, Allergic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.